Biosenic (FRA:BT1) Short-Term Debt

: €4.80 Mil (As of Jun. 2022)

View and export this data going back to 2015. Start your Free Trial

Biosenic's Short-Term Debt for the quarter that ended in Jun. 2022 was €4.80 Mil.

Biosenic's quarterly Short-Term Debt increased from Jun. 2021 (€0.81 Mil) to Dec. 2021 (€0.95 Mil) and increased from Dec. 2021 (€0.95 Mil) to Jun. 2022 (€4.80 Mil).

Biosenic's annual Short-Term Debt increased from Dec. 2019 (€2.53 Mil) to Dec. 2020 (€3.05 Mil) but then declined from Dec. 2020 (€3.05 Mil) to Dec. 2021 (€0.95 Mil).

Biosenic Short-Term Debt Historical Data

The historical data trend for Biosenic's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosenic Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Short-Term Debt

1.13

2.50

2.53

3.05

0.95

Biosenic Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
Short-Term Debt														6.82	3.05	0.81	0.95	4.80

Biosenic Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Biosenic Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Biosenic's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Biosenic (FRA:BT1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosenic (FRA:BT1) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

BIOS:Belgium

Address

Rue Auguste Piccard, 37, Gosselies, BEL, 6041

Website

https://www.bonetherapeutics.com

Bone Therapeutics SA is engaged in the development of cell therapy products for orthopaedics and bone diseases. The product pipeline of the company includes; ALLOB for treatment of delayed-union fractures, spinal fusion procedures and revision spinal fusion, and PREOB. In addition, the firm is also focused on conducting preclinical research on next-generation product candidates such as combined cell-matrix products for large bone defects and maxillofacial applications.

Biosenic (FRA:BT1) Headlines

No Headlines